Tirzepatide's Side Effects in High Cardiovascular Risk Patients Reviewed

Tirzepatide, a dual GIP and GLP-1 receptor agonist, is a highly effective treatment for type 2 diabetes and obesity, known for its significant weight loss and glycemic control benefits. Patients with these conditions often have an increased risk of cardiovascular events. While its efficacy is well-established, a comprehensive understanding of its adverse effect profile, particularly in this vulnerable population, is crucial. This systematic review and meta-analysis aimed to synthesize the evidence on tirzepatide's adverse effects specifically in patients with elevated cardiovascular risk.

The meta-analysis identified a higher incidence of gastrointestinal adverse events (AEs) commonly associated with GLP-1 receptor agonists. Specifically, nausea, vomiting, and diarrhea were reported significantly more often in tirzepatide-treated patients compared to control groups, though these were generally mild to moderate and transient. The study found no statistically significant increase in major adverse cardiovascular events (MACE) or other serious cardiovascular AEs with tirzepatide use in this high-risk population, suggesting a favorable cardiovascular safety profile. However, a minor increase in cholelithiasis (gallstones) and pancreatitis was observed, consistent with the known class effects of incretin-based therapies, though the absolute risk remained low. The Trial Sequential Analysis confirmed the robustness of these findings for common gastrointestinal AEs and the cardiovascular safety profile.